Osivax and KM Biologics sign deal for influenza vaccine in Japan
Under the terms of the agreement, KM Biologics will carry out the development, manufacturing, and commercialisation of Osivax’s vaccine. KM Biologics will make an upfront payment to Osivax
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.